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Steffen Flessa* and Anika ZembokAbstract
Background: Diabetes Mellitus Type II (T2DM) is a major and growing medical, social and economic burden in the
East-Asian country of Cambodia. However, no economic modelling has been done to predict the number of cases
and the budget impact.
Objective: This paper forecasts the epidemiological and economic consequences of T2DM in Cambodia. The
Ministry of Health and related donor agencies are supported to select the most cost-effective interventions against
the disease. At the same time this paper demonstrates the relevance and potential of health economic modelling
for least developed countries.
Methods: We developed a Markov-Model for the specific situation of Cambodia. Data was taken from the scientific
literature, grey literature in Cambodia and key-informant interviews.
Results: The number of people living with T2DM is steadily increasing from 145,000 in the year 2008 to 264,000 in the
year 2028 (+82 %). In the year 2008 the diagnosed T2DM patients would incur costs of some 2 million US$ to cover all
of diabetes treatment. 57 % of this amount would have to be spent for OAD-therapy, the rest for insulin therapy. In
the year 2028 this amount will have grown to some 4 million US$. If all patients (incl. non-diagnosed) had to be
paid-for the respective figure would be 5.5 million and 11 million US$.
Screening for T2DM is only cost-effective if the sensitivity of the test is high while the unit price is low. The results of
this simulation call for targeting the high-risk groups. However, an increased availability of Oral Anti-Diabetic and
Insulin Therapy is highly cost-effective.
Discussion: Type 2 Diabetes Mellitus is a major public health challenge in Cambodia. The simulations clearly indicate
that prevention and treatment of this disease is highly cost-effective. However, not everything that is cost-effective
might be affordable in Cambodia. This country will require external support to ease the growing burden of T2DM.
Keywords: Cambodia; Costing; Diabetes; Markov-Model; Prediction; South-East Asia; T2DMBackground
Diabetes Mellitus Type II (T2DM) is a non-communicable
disease (NCD) with a high prevalence and an increasing in-
cidence worldwide. The International Diabetes Federation
(IDF) estimates that about 350 million people are affected
worldwide and some 90% of diabetes patients live in low-
or middle-income countries [1]. IDF also expects a strong
increase of diabetes cases which will result in tremendous
human suffering, death cases and enormous costs of treat-
ment [2]. Thus, T2DM is a disease of high public health
importance and a good representative to analyse the eco-
nomic impact of NCDs on the health care system of
Cambodia and other low-income countries.* Correspondence: steffen.flessa@uni-greifswald.de
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reproduction in any medium, provided the origIn the year 2011 diabetes was top-8 cause of death world-
wide with 1,392,000 death cases (2.6% of all death cases
worldwide) and a rate of 20 per 100,000 inhabitants. For
South-East Asia (and the Western Pacific) WHO Region
the respective figures are rank 8 (8), 388,000 (284,000)
death cases, 2.8% (2.4%) of all death cases) and a rate of 21
(16) per 100,000. In the year 2000 diabetes had been only
on rank 10 worldwide and in the two target regions of this
paper [3]. Thus, diabetes is of high public health relevance.
It is one of the most prominent NCDs and a major cause
of morbidity and mortality worldwide as well as in South-
East Asia and the Western Pacific Region.
The South-East Asian country of Cambodia has a spe-
cific historical pathway that led to a late start of the epi-
demiological transition and a specific age structure. TheThis is an Open Access article distributed under the terms of the Creative
mmons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
inal work is properly credited.
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the Khmer Rouge period (1975–79). However, the popula-
tion of Cambodia is rapidly aging. As chronic-degenerative
diseases are mainly age-determined [4], it is extremely
likely that the absolute and relative importance of NCDs
such as T2DM is going to increase in Cambodia.
Currently the population is still rather young so that
the share of morbidity and mortality caused by NCDs
such as diabetes is slightly lower than in other coun-
tries of the region. The STEPS-Survey 2010 [5] records
a prevalence rate of T2DM of the adult Cambodians
(25–64 yrs.) of 2.9% (170,000 people), but there are
strong diversions between age groups, regions and gen-
der. Younger adults (23–34 yrs.) have a lower preva-
lence rate (1.1%); older groups (55–64 yrs.) a higher
rate (6%). The prevalence rate of the urban population
(5.6%) is much higher than of the rural population
(2.3%). At the same time, women (3.3%) are more affected
than men (2.5%). Other surveys [6] come to slightly differ-
ent figures but confirm the general finding that T2DM is
a major public health problem in Cambodia.
According to WHO, Diabetes causes 3,122 death cases
(2008) and a loss of 39,000 disability adjusted life years
(DALY) in Cambodia per year (2004, latest up-date of
WHO burden of disease database) [7]. IDF records 5,540
death cases in 2013 [8]. However, to our knowledge no es-
timate of the economic cost of T2DM from a society point
of view was attempted. However, this disease is the fourth
important NCD cause of death and the sixth importance
NCD cause of loss of quality of life in this country.
Prevention and treatment of T2DM in Cambodia is lim-
ited as the public health services do hardly provide any
diabetes care, T2DM is not included in the “basic package
of health care” and oral anti-diabetic drugs (OAD) and in-
sulin are not available in the whole country. The Royal
Government of Cambodia wants to address this rising dis-
ease and take care of its population, but for this purpose it
urgently needs a prediction of the expected number of
T2DM cases in Cambodia, determine the most cost-
effective intervention strategies, and estimate the budget
impact of prevention and treatment of this disease.
Unfortunately, no economic modelling of T2DM was
ever done in Cambodia. There are some cost estimates
from other South-East Asian countries, such as Indonesia
[9-11], Malaysia [12,13], Philippines [14-16], Thailand [17]
and Vietnam [14] but these cannot easily be transferred to
Cambodia with its unique age structure, economic situ-
ation and age structure. A very rudimentary costing comes
from the World Diabetes Foundation [18] which run a
project of diabetes care which cost 15.70 US$ per patient
annually or 6.00 US$ per consultation with all treatment
measures. Raguenaud et al. [19] estimated 48 US$ per year
(p. a.) for a glibenclamide mono-therapy and 192 US$ p. a.
of bi-therapy with glibenclamide and metformin. However,these figures are based on a pilot project of limited scope
and geographical extent. They cannot be taken as a stand-
ard for a public health intervention in the entire country
under the wings of the Ministry of Health.
Thus, our knowledge of the economic burden of T2DM
in Cambodia is as limited as our insights into the cost-
effectiveness of certain interventions in this country. There
is a great need to base decisions of the Ministry of Health
of the Royal Government of Cambodia as well as of the
international health partners on evidence. Consequently,
we have to make a micro-costing, a budget-impact and a
cost-effectiveness analysis of interventions against T2DM.
For this purpose we developed a Markov model of T2DM
in Cambodia which will be presented in the next section.
The results (to follow in section three) build the foundation
of the Annual Operational Plan of the Ministry of Health in
Phnom Penh. Consequently, our analysis takes the perspec-
tive of the Ministry of Health of Cambodia, but the insights
are of relevance to other least developed countries in par-
ticular in the South-East Asian region.
Methods
Context
Cambodia is a least developed country with a gross do-
mestic product of about 1,000 US$ (gross domestic prod-
uct in current US$ per capita in 2013) [20]. Although the
situation has improved within the last few years, still some
20% of the population is still below the official poverty
level permitting hardly to survive daily life.
The Ministry of Health finances first-line (health cen-
tres) and second-line (hospitals) health facilities. However,
patients have to pay modest fees. The services of these fa-
cilities are defined by the Ministry of Health as a so-called
“basic package of health care services” [21]. Currently, this
package includes only prevention and treatment of com-
municable diseases as well as diagnosis related to mater-
nity. Due to financial constraints, NCDs are not included
in this package although it is generally accepted that they
have a high priority [22]. Cambodia spends about 50 US$
per annum per capita [20]which is not enough to include
chronic-degenerative diseases in the basic package.
The population under the poverty-line is exempted from
paying the fees by a system called “Health Equity Fund”
(HEF). The health care provider receives the equivalent
amount from the HEF which is partly financed by the
international donor community and the Royal Government
of Cambodia. However, if a patient suffers from a disease
which is not covered by the basic package (such as dia-
betes) he has to seek services from private providers who
usually charge fees unaffordable for the majority of the
population. Thus, very limited treatment is available for
the majority of diabetic patients.
Most diabetic patients are undiagnosed until they have
severe complications as no blood-sugar testing is usually
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quently only available in private pharmacies for high prices,
even those who are diagnosed will receive proper treatment
only if they can afford it. The same is true for insulin. Con-
sequently, self-help groups and “peer-educator” groups [23]
have been started. MoPoTsyo (Patient Information Centre),
for instance, supports diabetes patients with drugs and in-
sulin. At the same time it teaches them to become peer
educators for their villages. This includes the search for po-
tential diabetic cases. Peer Educator Networks have been
accepted by the Government as an important contribution
to the fight against NCDs [22], but until now no funds are
allocated by the Ministry so that most Cambodians remain
without any support if they develop diabetes.
Model
The analysis follows the standards of health economic
evaluation stipulated by Schulenburg et al. [24] and takes
the perspective of the Ministry of Health of Cambodia.
The calculation and prognosis of the costs of different in-
terventions against T2DM is of high importance for this
Ministry. In addition, the Ministry of Health is obliged to
include only new interventions into the basic package
of services if they are cost-effective in comparison to
other possible interventions. Thus, we also calculate the
incremental cost effectiveness ratio (ICER) as this is a pos-
sible statistic that allows comparing the cost-effectiveness
of possible candidates to be included into the basic
package.
As diabetes is an NCD the likelihoods of developing dia-
betes or transitioning to another stage of the disease are
constant. Consequently, the epidemiology of T2DM is fre-























Figure 1 Markov Graph (variables refer to (Table 1)).only few models were designed for resource-poor countries
[26]. None represents the specific structure and parameters
of the Cambodian demography and the health care system.
Thus, it was necessary to design a specific model and
search for the relevant parameters of Cambodia.
The model simulates age-sets of 5 years for adults
(>15 yrs.). The simulation runs from 2008 to 2028. As
the prevalence of T2DM in the age set < 35 is negligible,
we concentrate on the cohort ≥ 15 years in the year
2008. Figure 1 shows the principle structure of the Markov
model recalling the biological life of a T2DM patient.
Every year 1/5th of the population is transferred to the
higher age-set. At the same time, a certain part of the
healthy population will die. The parameter p_death_rest
is the non-T2DM related rest mortality for a certain
age set. Another part of the healthy population will de-
velop uncomplicated (and undiagnosed) diabetes. The
respective share is denoted as p_T2DM and is age-
specific for each age-set.
An undiagnosed diabetic case without complications
can either stay in this condition or develop complications.
For each complication (diabetic nephropathy, retinopathy,
neuropathy, angina pectoris, peripheral vascular disease
(PVD), myocardial infarction, stroke, heart failure) the re-
spective transition probabilities (e.g. p_retino; p_neuro;
p_stroke…) are applied. The patient can also die from dia-
betes (e.g. p_stroke_death) or non-diabetes (p_death_rest).
If the patient is diagnosed (with a likelihood of p_diag-
nose_early) he will be under diet. Again, the patient can
stay in this compartment, develop complications, receive
OAD or die from diabetes or any other cause. The re-
spective transition probabilities are given in the (Table 1).




















Table 1 Basic parameters
Parameter Explanation Value Source
p_death_rest non-T2DM mortality age-specific [27]
p_T2DM age-specific incidence of T2DM age-specific [28]
p_Diagnosis_late probability of clinical diagnosis with persisting complications 0.2 Assumption
p_Diagnose_early probability of clinical diagnosis without complications or in the first year after development of
complications
0.08 Assumption
p_OAD probability of change of therapy to OAD-therapy 0.98 Assumption
p_Insulin probability of change of therapy to OAD/insulin or mono-insulin 0.04 [29]
p_Insulin_Adherence share of patients taking insulin in those requiring it 0.125 [30]
p_OAD_Adherence share of patients taking OAD medication in those requiring it 0.125 [30]
p_stroke_death stroke-related mortality 0.38136 [31]
p_MI_death myocardial infarction-related mortality 0.7068 [31]
p_nephro incidence diabetic nephropathy 0.01479 [32]
p_retino incidence diabetic retinopathy 0.02124 [33]
p_neuro incidence distal symmetric neuropathy 0.04658 [34]
p_Angina incidence angina pectoris 0.00668 [31]
p_PVD incidence PVD 0.00847 [35]
p_MI incidence myocardial infarction 0.01735 [31]
p_stroke incidence stroke 0.00529 [31]
p_heartfailure incidence heart failure 0.00329 [31]
c_Diagnosis unit cost FPG-test 1.00 USD [36]
c_ambulatory Annual cost outpatient treatment 2.66 USD [36,37]
c_Laboratory Annual cost laboratory exams 1.28 USD [36,38]
c_OAD Annual average cost for OAD medication 24.85 USD [36,38,39]
c_Insulin Annual average cost for insulin therapy (weighted mean for monotherapy and insulin-OAD-
combined therapy)
114.26 USD [36,38,39]
c_Hospital Annual average cost for inpatient treatment 35.89 USD [40]
*adjusted.











Diagnoses lag [47] Adjusted
Therapy options [48] Adjusted
Cost [39,40] Own calculations based on MoPoTsyo
data from Phnom Penh
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velop complications or die with certain likelihoods.
The mathematical prognosis follows a standard approach.
The vector wt represents the number of individuals in the
specific health states (e.g. “healthy”, “undiagnosed, no com-
plications”, “undiagnosed, complications”, “diet”, “OAD, no
complications”, “insulin”, “OAD, complication”, “insulin,
complication” “non T2DM death”, “T2DM death”) in
time t. The respective vector wt+1 for the next period (t + 1)
is calculated by multiplying the vector with the matrix
of transition probabilities A [41], i.e.









a11 a12 … a1n
a21 a22 … a2n
⋮ ⋮ ⋱ ⋮





Consequently, the number of individuals in the spe-
cific health states in time t is calculated as wt ¼ w0⋅ At
where w0 denotes the vector of the numbers of individ-
uals in the conditions in the beginning of the simulation.Data
Table 2 exhibits the most important parameters and the
sources. Where no country-specific data was available, we
used international data and adjusted it to Cambodia. For
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experts with the international data and asked them for
their assessment of the relevance for Cambodia. With these
estimates we firstly simulated the demographic and epi-
demiological development from 1988 to 2007. The results
of these simulations were compared with the real figures
from Cambodian statistics [42]. Finally, we adapted the pa-
rameters until the simulation fitted the reality to a best
possible extent. This “calibration process” (e.g. [43]) was
also used to adjust the transition of stages. As it is esti-
mated that diabetes manifests about 10 years earlier in
Asian countries than in Europe [44] the respective statistics
had to be fitted. This standard approach of disease model-
ling under uncertainty calls for a set of sensitivity analyses
which are presented in section Sensitivity analyses. The
basic parameters are also expressed in the (Table 1).
The treatment costs are crucial so that detailed analysis
was done based on the data of MoPoTsyo [36], data from
WHO-CHOICE [37], the international drug price indica-
tor guide [39] and additional research on market prices in
Cambodia [38]. The costs of Metformin and of Glibencla-
mide were estimates as 25 US$ and 3 US$ p.a. p.c. With
the assumption that 12% use mono-therapy of Metformin,
10% mono-therapy of Glibenclamide and 78% the
bi-therapy the average cost per OAD-patient are about
25 US$. The cost per ml of insulin were estimated with
0.72 US$ [39]. At an average consumption of 10 ml we
have annual cost of 86 US$ for insulin and 17 US$
for syringes. The combined therapy was estimated to
cost 129 US$ p.a. p.c. Assuming that international
standards [39] apply to Cambodia we reckoned that
57% of insulin requiring T2DM patients receive a
monotherapy the average cost of insulin therapy is 114
US$ p.c. p.a. As far as not stated differently, all values
















Figure 2 T2DM cases – basic simulation.Based on these parameters we made a forecast of the epi-




The basic simulation projects the epidemiological and eco-
nomic consequences if the Government does not change
its current policy, i.e., if the prevention and treatment of
T2DM is not included in the basic health care package. In
this case, only 12.5% of people requiring OAD and insulin
can afford them by own funds or has access to them by
charitable organisations. The basic simulation assumes that
this rate remains stable.
Figure 2 shows the development of diabetes in
Cambodia under this condition. The number of people
with T2DM is steadily increasing from 145,000 in the
year 2008 to 264,000 in the year 2028 (+82%). At the
same time the population of this age set increases by
67%, i.e., the prevalence rate increases from 4.0% to 4.4%
in the age group ≥ 35 yrs.
The majority of T2DM cases remain undiagnosed. The
rate is almost stable (63–64%) as the basic simulation as-
sumes that no additional interventions are implemented.
The number of diagnosed patients with complication, how-
ever, is increasing to a higher extent than the number of di-
agnosed patients without complications. In 2008 59% of
diagnosed patients had complications, in the year 2028 this
rate will have increased to 68%. This is due to the fact that
the aging population and the longer duration of diabetes
will result in more cases with complications.
Figure 3 shows the number of diagnosed T2DM cases
requiring different forms of therapy. “Diet” means that a di-
agnosed patient does not receive any medication. Regularly


















Figure 3 T2DM therapies – basic simulation.
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2008, 2% would not require any form of medication, 84%
would need OAD-therapy and 14% insulin. In the years
2028 8% of diagnosed cases will not require medication,
76% need OAD-therapy and 17% insulin therapy. Thus, a
higher share of the population will be in the severe state of
requiring insulin. The increase of 114% is much higher than
the increase of the total number of diabetic cases in
Cambodia. The decision-makers in Cambodia can expect
that the worst medical and economic consequences of
T2DM are still to come!
This is also reflected by the steadily increasing cost of
treatment of patients with T2DM in Cambodia (Figure 4).
In the moment, it is estimated that 12.5% of people
requiring OAD- and insulin therapy do actually re-




















Figure 4 Budget impact of T2DM – basic simulation.figures remain stable. A scenario that accounts for in-
creasing coverage with medication will be presented
in section Oral Anti-Diabetic therapy.
In the year 2008 the 54,000 diagnosed T2DM patients
would incur costs of 2 million US$ to cover all of diabetes
treatment. 57% of this amount would have to be spent for
OAD-therapy, the rest for insulin therapy. In the year 2028
this amount will have grown to 4 million US$ to cover
97,000 patients. If all patients (incl. non-diagnosed) had to
be paid-for the respective figure would be 5.5 million US$
and 11 million US$. These calculations assume stable prices
and no discounting. Thus, the costs will double due to a
shift of patients towards the expensive patients with com-
plications and requiring insulin. The expected average cost
per diagnosed diabetic patient p. a. was 38 US$ in the year
2008 and will be 42 US$ in the year 2028.2018 2023 2028
 [years]
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the parameter estimates. Most critical is the estimate of the
hospital cost. An increase of the cost by 50% leads to an in-
crease of the cumulated cost by 40%, whereas the respective
increase of the OAD-medication will result only in an in-
crease of the total cost of 6%. Another critical parameter is
the general and T2DM-related mortality. The earlier people
die, the lower will be the cost. If the T2DM-related mortal-
ity increases by 20%, the cumulative cost will decrease by
16%. If the general mortality increases by the same rate, the
respective decrease will be 17%. Even if we change all
parameters towards the “best” possible case (according to
estimates from the literature and from Cambodian experts),
the budget requirement will increase until 2028.
In summary, Cambodia is facing an increasing num-
ber of diabetic patients requiring OAD- and insulin
therapy. If the Government includes prevention and
treatment of T2DM in the basic package, these costs
will have to be refinanced by the Government even if
the share of patients under treatment remains stable.
Compared with the actual budget of the Ministry of
Health these amounts seem not too high – but we have
to keep in mind that they are additional to the existing
expenditure for health care! Thus, there is a need to
analyse the cost-effectiveness of interventions and select
the best use of scarce resources.
Screening programs
The basic simulation assumes that a patient is on average
undiagnosed for seven years [47]. Consequently, treatment
can only start late. At the same time, complications, early
transition to higher states and diabetes-related death are
higher than necessary. The purpose of screening programs
is to determine T2DM cases as early as possible, ideally at
the on-set of the disease to avoid these negative conse-
quences. The impact of screening on the epidemiology and
cost depends on the share of the population screened (e.g.
only high-risk groups or total population) as well as on the
sensitivity of the test. Without doubt, detecting every dia-
betic patient within one year will be technically impossible.
However, in a first step we would like to present this utopic
scenario of perfect screening, in the second step we will
analyse the consequences of lower screening sensitivity
and reduced coverage.
As first step we calculated the model for the case of the
ideal screening program that detects every patient within
one year after the on-set of T2DM. The consequences are
an increase of the number of people living with T2DM and
a strong decline of the number of T2DM-related death
cases. In the year 2028, for instance, 275,000 people will live
with T2DM instead of 264,000. The cumulative number of
T2DM-related death cases from 2008 to 2028 will be
462,000 instead of 476,000. The share of diagnosed diabetics
with complications sinks from 68% to 48%, and morediabetic cases need no medication (12% versus 8%). The
total cumulative treatment costs increase from 61 to 68 mil-
lion US$. However, the average cost per diagnosed diabetic
patient of the year 2028 declines from 42 US$ to 33 US$.
The incremental cost-effectiveness ratio (ICER) com-
pares the cost of an intervention with the effect (e.g. years
of life saved, lives saved). An intervention is usually
assessed as cost-effective if the cost per life-year saved
(LYS) is less than the annual gross national product per
capita (p.c.). In the case of Cambodia, an intervention is
cost-effective if the ICER is less than 1,000 US$. If we as-
sume the cost of urine sugar screening done by MoPoTsyo
(i.e. 0.07 US$ p. c. plus 1 US$ for the confirmation test)
the corresponding ICER is 464 US$/YLS, i.e., screening
the entire population > 35 years annually for T2DM is
cost-effective if the sensitivity is 100%.
In the second step we vary the coverage (share of
population covered) and the sensitivity of the test. If we
assume that 100% of the population are screened the
cost per screening could be 1.05 US$ if the screening
is 100% sensitive, 0.64 US$ if the sensitivity is 75% and
0.23 US$ if it were 50% sensitive. If the sensitivity goes
below 36% screening will not be cost-effective at all.
If we focus on risk groups and reduce the coverage of
the population the cost per screening could be higher.
Every combination of coverage (x-axis) and cost (y-axis)
to the lower-left of the curves of Figure 5 is cost-
effective. If we limit, for instance, screening to 33% of the
adult population ≥ 35 yrs. the cost per screening could rise
to 3.18 US$ (sensitivity 100%), 1.93 US$ (sensitivity 75%)
and 0.69 US$ (sensitivity 50%). For instance, limiting
screening to the obese allows even higher unit costs while
still safeguarding cost-effectiveness of the intervention. In
the discussion we will address this issue again.
Oral anti-diabetic therapy
OAD is not included in the basic package of health care
services in Cambodia. Consequently, these drugs are only
available for the very few protected by private health insur-
ances or for those who can afford to pay for these drugs
out-of-pocket. Consequently, it is estimated that only 12.5%
of those diagnosed diabetics requiring OAD-therapy com-
ply [30,49]. In this section we will analyse the consequences
of improved access to OAD-therapy. This could, for in-
stance, be possible if the Royal Government of Cambodia
provides free or highly subsidized access to these drugs at
rural health centres, i.e., if OAD medication becomes an
element of the basic package of health care in Cambodia.
Figure 6 exhibits the consequences of improved cover-
age of OAD-therapy on years of life saved and death
cases averted. As expected, a higher degree of patients
who require medication and receive medication leads to
a higher number of years of life saved and death cases

























Share of population > 35 screened
s=1 s=0.75 s=0.50
Figure 5 Cost-effectiveness area of screening.
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are saved and 25,000 death cases are averted from 2008
to 2028. The percentage of diagnosed diabetics receiving
OAD-therapy increases from 76% to 78%, but also the
total number of people living with diabetes increases in
all compartments of diagnosed diabetics. Thus, there are
more people requiring insulin than before as more people
survive the disease for a longer time. Consequently, the
cost of diabetes treatment strongly increases, i.e., improv-
ing coverage of the population by OAD-therapy does not
only require more resources to fund OAD-drugs but also
to finance insulin for the higher number of patients who
survived the OAD-phase. Consequently, the cost per dia-
betic patient increase from 42 US$ to 53 US$.
Figure 7 shows the present value of the marginal cost
of improved OAD-coverage. The costs increase monot-
onously with increased coverage. However, the ICER is
almost stable. An increase of coverage from 13% to 25%
has an ICER of 102 US$ per YLS, an increase from 13%
to 100% of 102 US$ (discounted with 5%). The respect-
ive figures for death cases averted are 841 (25%) and 780
US$ (100%) per death case averted, i.e., a higher cover-
age even improves the cost-effectiveness.
An ICER of 100 US$ per YLS is highly cost-effective, and




























YLS Death cases averted
Figure 6 Impact of different scenarios of coverage
of OAD-therapy.a rate of 7.5% the ICER merely increases to 105 US$/YLS.
However, cost-effectiveness does not imply feasibility as
the budget constraints have to be respected. In the year
2028 Cambodia would have to spend 6.7 million US$
instead of 4 million US$ if all patients requiring OAD-
therapy had access to this medication. A difference of 2.7
million US$ p. a. is significant for the National Budget.Insulin therapy
Insulin therapy in Cambodia is quite expensive and difficult
to obtain. Consequently, it is estimated that only 12.5% of
those requiring insulin therapy have access to it [30,49]. In
the following we will analyse the consequences of improved
access to insulin therapy.
Figure 8 shows the impact of different coverage rates
of insulin therapy on the number of death cases averted
and the years of life saved. As expected, many death cases
will be averted and many years of life saved if more dia-
betic patients requiring insulin have access to it. If all pa-
tients requiring insulin receive it 43,000 years of life will
be saved and 5,800 death cases averted between 2008 and
2028. The number of people living with insulin therapy in-
creases so that the share of diabetic patients with insulin
therapy among all diagnosed diabetic patients increases
from 17% to 22%. Consequently, the total cost increases
from 42 US$ to 63 US$ per diagnosed diabetic case.
Figure 9 shows the present value of the additional cost
caused by improved access to insulin for the period 2008
to 2028. If the insulin coverage increases from 12.5% to
25% the present value of these additional cost will be 2.3
million US$, if the entire population is covered it will be 20
million US$. Insulin therapy is quite expensive per person,
so that the cost-effectiveness of improved access to insulin
is lower than the cost-effectiveness of a higher coverage by
OAD-therapy. The ICER is 451 US$ per YLS if the access
improves from 12.5% to 25%. For an increase from 12.5%





























Figure 7 Marginal cost of different scenarios of coverage of OAD-therapy.
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in Cambodia, but not as effective as improved access to
OAD-therapy. From a purely economic perspective, im-
proving OAD-therapy would have a higher priority than
insulin therapy. However, patients requiring insulin are
most likely suffering more than patients who can still deal
with OAD-therapy. Thus, insulin therapy must have a high
priority. However, the cost of improved access to insulin is
considerable. If all patients requiring insulin are to receive
full insulin coverage the additional cost of the year
2008 will be 2,473,319 US$, i.e., 6.5 million instead of
4.1 million US$. Cambodia will have to seek funds for
this additional demand.
Combined intervention
In most countries neither screening nor OAD- and insu-
lin therapy are stand-alone interventions. A combined



































Figure 8 Impact of different scenarios of coverage of insulin therapy.Cambodia. Consequently, the last scenario analyses the
consequences of introducing a “perfect” screening pro-
gram and fully covering all patients requiring OAD- or
insulin therapy.
The consequence of this optimal prevention and treat-
ment approach is impressive: 582,000 years of life are
saved and 78,000 death cases (−27%) are averted within
the simulation period. The number of diagnosed diabetic
cases increases from 37% to 90%. Among the diagnosed
patients, the rate of those with complications declines
from 68% to 51%. More patients do not require any
medication (9% instead of 8%), but also more patients
require insulin (21% instead of 17%).
However, substantial resources are needed to achieve
these results. The annual budget for professional diabetes
prevention and treatment in the year 2008 would be 8
million US$, i.e. 3.9 million US$ more than the current































Figure 9 Budget impact of different scenarios of coverage of insulin therapy.
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respective age group (≥35 yrs.) will be living in Cambodia
by then so that the costs of mass screening would be
substantial. Assuming that the unit cost calculated for
MoPoTsyo are representative for the entire country (0.07
US$ per screening unit) we could add 429,000 US$ just for
screening. However, the ICER is still quite favorable. With-
out cost of mass screening it is 203 US$ per YLS (r = 5%),
with mass screening 215 US$/YLS. Consequently, from a
health economic perspective diabetes prevention and treat-
ment is highly recommendable.
Sensitivity analyses
The results of the basic simulation and the intervention
analyses strongly depend on the reliability of the param-
eters. Until today the most serious problem of any mod-
elling of (health) economic interventions in developing
countries is the “the almost complete unreliability of
what data is available and the absence of any recent
data” [50]. Therefore, we conducted sensitivity analyses
to assess the reliability of the predications. Parameters
which were certain (e.g. fertility) were not included in
the sensitivity analysis.
Figure 10 shows the impact of a change of parameters
on the cumulative patient years (r = 5%). In absence of
reliable minimum or maximum values of the parameters
we increased or decreased all parameters by 20%. Merely
the discounting factor was altered by ±50% (i.e. between
2.5 and 7.5%). Figure 10 includes only those parameters
where the consequences of the respective increase or de-
crease are significant.
We realize that changes of the mortality and the inci-
dence have a strong impact on the cumulative number of
patient years. The incidence expresses the likelihood that
a patient in the status “healthy” develops T2DM within a
period. A change of this parameter will have a stronger
impact on the epidemiology. Another important factor is
the non-T2DM-related mortality (“rest mortality”). Thehigher the likelihood to die from any other cause of death,
the lower is the number of patient years. In addition, pa-
tients who would require a certain treatment but cannot
receive it will have a higher mortality (increase mortality
non-compliance). The higher this increase, the lower is
the cumulative number of patient years. All other vari-
ables have very limited impact on the patient years. It
should also be noted, that all changes of parameters have
under-proportional impact on the patient years.
Figure 11 shows the consequences of a change of basic
parameters on the present value of the cost of T2DM in
Cambodia from 2008 to 2028. Again we included only
those parameters where the increase or decrease had a
significant influence. As expected, the hospital unit costs
have the highest impact on the total cost of T2DM, but
also the likelihood of developing diabetes (incidence) and
the cost of medication (OAD and insulin) have a major
impact. At the same time an increase of mortality (rest
and increase due to non-compliance) and a higher dis-
counting factor will decrease the present value of the cost.
It becomes visible that the cost containment and the
proper analysis of hospital accounts are crucial.
In addition, we calculated a “best-case” and a “worst-
case” scenario as a multivariate sensitivity analysis. “Best”
here means that all parameters (except the discounting
factor) are altered by 20% so that the cumulated patient
years are higher and costs are lower than in the basic sce-
nario. “Worst” means an increase or decrease in the other
direction. Table 3 shows the results. The range between
the “best” and “worst”-case scenario is tremendous. If we
estimate for all parameters the “worst” value the present
value of cost will be almost three times as high as in the
basic scenario. Here it is important to note that wrong es-
timates of all epidemiological probabilities (e.g. mortality,
incidence) are worse than a wrong estimate of unit costs,
but a wrong estimate of all parameters is much worse.
Consequently, there is a great need for further re-
search on basic epidemiological parameters and unit
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Figure 11 Sensitivity of present value of cost.
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Figure 10 Sensitivity of cumulative patient years.
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Table 3 Best- and worst-case scenario
Scenario Variant Present value of cost [US$] Difference
Basic 37,119,499 -
Worst-case Probabilities 72,203,153 95%
Unit cost 55,679,249 50%
Probabilities and unit cost 108,304,730 192%
Best-case Probabilities 18,691,093 −50%
Unit cost 18,559,750 −50%
Probabilities and unit cost 9,345,546 −75%
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model and the interventions are better than anything
else in the literature – but they have to be taken with
some caution. However, it is very unlikely that all pa-
rameters will be wrong so that this data can be taken as
a starting-point of discussion.Discussion
Type 2 Diabetes Mellitus is a major public health challenge
in Cambodia. Currently 170,000 inhabitants are estimated
to have the disease [5], but health planners have to expect
higher rates in future. The Markov model calculates that
the number of cases of T2DM was 172,000 in the year
2013 and will grow to 264,000 in the year 2028. Based on
the population ≥ 35 yrs. this will correspond to a prevalence
rate of 4%. There is no doubt that the Ministry of Health,
the Civil Society and health partners will have to invest ef-
fort to prepare for this “epidemic” of T2DM in Cambodia.
IDF [51] projects 364,000 diabetic cases in the year 2030
for Cambodia, but their model is rather simplistic in com-
parison to our Markov model. However, we have to accept
that our forecast might underestimate the reality to come
as we assume that transition probabilities remain constant.
This means, for instance, that the likelihood of developing
T2DM at a certain age remains stable through the simula-
tion period. This assumption might be wrong if nutritional
habits and physical exercise change. With the availability
of processed food even in rural areas and the reduction of
the share of population engaged in physical work it might
be that our estimates turn out to be too conservative.
However, even at given transition probabilities the eco-
nomic burden of T2DM for Cambodia is tremendous.
Chronic complications are the main cost driver, and their
number is increasing with time. The model calculates that
65,711 cases would require additional treatment for chronic
complications in the year 2028. This results in a strong in-
crease of cost from 2008 to 2028, i.e. from 2 million US$ to
4 US$. This refers to average annual cost per diabetic case
of 42 US$.
Prevention and treatment of T2DM is not only a finan-
cial problem. Currently, the majority of health care workersin rural health centres are not well trained in the detection
of cases and treatment of patients. Cambodia will have to
invest effort to train their doctors, nurses and other health
professionals in the prevention and treatment of NCDs,
such as diabetes. As the numbers increase, there is an ur-
gent need to intensify the existing training programs and
tailor them even more towards NCDs.
At the same time Cambodia has to safeguard a stable
supply of OAD-medication and insulin (including syrin-
ges etc.). This as well is not only a financial challenge.
Cambodia is a tropical country where temperatures eas-
ily go up to 40 degrees Celsius. Thus, insulin requires an
uninterrupted cooling chain. For most people in rural
areas refrigerators are an unaffordable luxury. Providing
community cooling systems for people living with dia-
betes (e.g. one per village) could be discussed. However,
logistics will remain an issue.
The cost estimates for diabetes treatment differ widely
within studies from South East Asia. Andayani &
Imaningsih estimated a figure of 239.64 US$ p. a. for
one Indonesian hospital, Andayani [11] calculated an-
nual cost of 252.00 US$ for another hospital of this
country. The direct cost which Ibrahim et al. [13] calcu-
lated for Malaysia (572.70 US$ p. a.) and Chatterjee
et al. [17] for Thailand (555.33 US$) are even higher.
However, the differences between these figures and the
results of the simulation presented in this paper are the re-
sult of the very low cost of the Cambodian health system.
Martin [52] found in her cost study of Cambodian public
health services that the average cost of a health centre out-
patient visit were 1.00 US$, the average inpatient case in
the medical department of a district hospital (CPA-1) had
costs of 20 US$. This is only a fraction of what it would
cost in Thailand, Malaysia or Indonesia.
The low cost of Cambodian health services and the low
financial resources required to prevent and treat T2DM in
Cambodia reflect the different economic parameters of
the respective countries. As Table 4 shows, Thailand
and Malaysia are upper-middle income countries [53]
with a national income per capita that is 5.5 and 11.1
(in US$) resp. 4.0 and 6.7 (in Int. US$) times higher. It
is expectable that treating patients in these countries is
Table 4 Economic data of South-East Asian countries 2012
Income classification GNP [US$] GNP [Int. US$] Cost estimates [US$ p. a.] GNP/cost
Cambodia Low 944 2330 42 22.5
Thailand Upper-middle 5210 9280 555 9.4
Malaysia Upper-middle 10432 16270 573 8.2
Vietnam Lower-middle 1755 3620 - -
Indonesia Lower-middle 3557 4730 240-252 14.1-14.8
Philippines Lower-middle 2587 4380 - -
Source: [54].
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Philippines are lower-middle income countries. The
GNP p. c. is also much higher. Laos and Myanmar
would be much more comparable, but to our know-
ledge there is no data on the cost of diabetes in these
countries.
As demonstrated in section Results the results of this
simulation are highly sensitive to changes of the cost per
service unit in hospitals. The model used the average cost
per patient in medical departments of Cambodian hospi-
tals as presented by Martin [52]. To our knowledge no
cost analysis exists analysing the exact cost per diabetic in-
patient case in Cambodia. This calls for further research.
In addition, the cost estimates of Martin reflect the situ-
ation of public health care providers. The costs of private
providers are much higher. If we assume that private pro-
viders are included in diabetes care in Cambodia the cost
will strongly increase and the cost-effectiveness of interven-
tions will decrease. The Royal Government of Cambodia
might make public-private partnership agreements to safe-
guard country-wide professional diabetes care while con-
taining the costs.
The economic development of the country until 2028
will have two consequences. On one hand side, it is
most likely that prices and wages will increase so that
some of the cost estimates of this paper will be obsolete.
However, the public budget will also increase. It is notFigure 12 Cost-effectiveness of screening with blood glucoses test.yet determined whether the prices and wages of the health
care sector will grow stronger or less than the public
budget. If the prices and wages increase with the same rate
as the gross national income but the national budget
grows at a lower rate it is possible that the ICER of inter-
ventions remains constant but the feasibility to finance
these interventions declines.
Our simulations show that improved access to OAD-
medication and to insulin is cost-effective for Cambodia.
The Royal Government of Cambodia should be advised
to include professional treatment of T2DM patients in
its basic package of health care services. Even a slight in-
crease of coverage (from currently 12.5% to 25%) has
already a tremendous impact on mortality and life years.
The cost-effectiveness of screening for T2DM depends
on some parameters. Firstly, screening is cost-effective
only if the sensitivity of the test is high enough. How-
ever, urine sugar tests might not be sufficiently precise
as they might have a high number of false-negative cases
in particular if made only once. They are inexpensive –
but if the sensitivity is not at least 37% they will not be
cost-effective even if we could limit the screening popu-
lation to 1% of the adults. The estimates of the sensitivity
of urine glucoses tests in the literature do not give a clear
answer. Davies et al. estimated a sensitivity of 43% [55],
Hanson et al. of 64% [56], Friderichsen and Maunsbach of
21% [57]. Other authors showed that the sensitivity
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glucoses intake [58]. Under the conditions of a Cambo-
dian rural health centre, a urine blood sugar test is fre-
quently quite unreliable. However, as the WHO rightly
puts it: “Despite its low sensitivity, urine glucose testing
may have a place in low resource settings where no
other procedure is possible. This is particularly so, of
course, when the prevalence of undiagnosed diabetes is
likely to be high” [59].
This indicates, secondly, that some concentration on risk
groups must be sought to safeguard cost-effectiveness of
screening. The risk factors obesity and low physical activity
predict a high share of diabetic patients, but even focussing
on only 10% of the population with a test with 50% sensi-
tivity would not allow costs of more than 2.26 US$ per test
to be cost-effective. Figure 12 shows the cost-effectiveness
areas of screening with blood glucoses test assuming that
one test costs 1.28 US$ [40]. All combinations to the
lower-right of the curve are cost-effective.
Conclusions
The simulations show that prevention and treatment of
T2DM can be cost-effective even under the conditions
of a least developed country like Cambodia. However,
we must be aware that providing preventive and curative
health care services at the point of provider is only one
component of managing T2DM. Frequently undiagnosed
diabetic cases will not show-up in health centres because
they live too far away, have no transport or no time, or
do not perceive any symptoms which would lead to a
visit for diagnosis or therapy. At the same time, diag-
nosed patients might not comply with the instructions
of the professional health care workers. Consequently,
community-based approaches will be required that find
potential patients, help them obtain professional help
and improve compliance. The peer-educator network
MoPoTsyo is such a community-based system that has
shown the capability of strongly improving the situation
of people living with T2DM. The Strategic Plan [22]
foresees a nation-wide role of such networks in the fight
against T2DM. The Ministry of Health could learn from
the experiences of MoPoTsyo.
Diabetes is a great challenge to all stakeholders of the
Cambodian health sector. It has financial, medical, demo-
graphic and social implications. However, the main chal-
lenge might be to develop another mind-set while
addressing this chronic-degenerative disease. Until now,
the entire health care system is based on the infection
paradigm. One agent (e.g. plasmodium) causes one disease
(malaria) and the connection between both is almost lin-
ear and deterministic. Consequently, seeking for the one
cause, preventing or eliminating it is sufficient to provide
proper health care. Chronic-degenerative diseases such as
T2DM, instead, follow a multi-cause-multi-effect model,i.e., many risk factors and conditions contribute to their
development (incl. a genetic risk). At the same time, the
same set of risk factors might cause none or very different
NCDs as no simple deterministic relationship between
causes and effects exists. Consequently, a new focus on
NCDs will require a new thinking about medicine, health
care and the engagement of the health partners. Type 2
Diabetes Mellitus might be a door-opener to this different
paradigm of health care in Cambodia.
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